Tevogen Bio advances cell therapy TVGN 920 for HPV-associated precancerous cervical lesions using ExacTcell technology.

Tevogen Bio is advancing cell therapies to treat HPV-associated precancerous cervical lesions in women, using its investigational product TVGN 920. This therapy aims to eliminate HPV, preventing recurrent lesions and potential cervical cancer. Utilizing its ExacTcell technology, Tevogen targets specific areas of the HPV genome. The company's broader goal is to provide personalized immunotherapies for significant health needs in large patient populations.

October 15, 2024
4 Articles

Further Reading